INS and Hypoglycemia: This mechanism provides a relatively flat PK profile with minimal peak activity and maintains glucose-lowering effects for up to 24 h and more closely resembling endogenous basal insulin secretion, reducing nocturnal hypoglycemia by 40% compared to NPH insulin, while improving patient compliance through once-daily dosing (63)(Table 4).